|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Vigil Neuroscience insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Vigil Neuroscience insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-20-2023 Insider Buy |
Ivana Magovcevic-liebisch President and CEO |
$3.75
CAGR »
|
$15,000.00 4,000 shares |
5-17-2022 Insider Buy |
Clay Thorp Director |
$2.85
CAGR »
|
$104,410.50 36,695 shares |
5-5-2022 Insider Buy |
Evan Thackaberry SVP, Head of Early Development |
$4.00
CAGR »
|
$6,000.00 1,500 shares |
5-3-2022 Insider Buy |
Spyros Papapetropoulos Chief Medical Officer |
$3.40
CAGR »
|
$13,591.20 4,000 shares |
5-3-2022 Insider Buy |
Jennifer Lynn Ziolkowski Chief Financial Officer |
$3.77
CAGR »
|
$15,097.60 4,000 shares |
5-3-2022 Insider Buy |
Ivana Magovcevic-liebisch President and CEO |
$3.68
CAGR »
|
$18,379.00 5,000 shares |
5-3-2022 Insider Buy |
Christopher Verni General Counsel |
$3.77
CAGR »
|
$15,074.40 4,000 shares |
3-28-2022 Insider Buy |
Clay Thorp Director |
$7.20
CAGR »
|
$21,604.20 3,000 shares |
1-11-2022 Insider Buy |
Atlas Venture Fund XII, L.P. >10% Owner |
$14.00
CAGR »
|
$7,490,000.00 535,000 shares |
1-11-2022 Insider Buy |
Ventures GP Iii, L.L.C. Vida >10% Owner |
$14.00
CAGR »
|
$23,450,000.00 1,675,000 shares |
1-11-2022 Insider Buy |
Clay Thorp Director |
$14.00
CAGR »
|
$3,710,000.00 265,000 shares |
1-11-2022 Insider Buy |
Stefan Vitorovic Director |
$14.00
CAGR »
|
$23,450,000.00 1,675,000 shares |
1-11-2022 Insider Buy |
Bruce Booth Director |
$14.00
CAGR »
|
$7,490,000.00 535,000 shares |
1-11-2022 Insider Buy |
Northpond Ventures GP, LLC >10% Owner |
$14.00
CAGR »
|
$4,970,000.00 355,000 shares |
Also See: Institutional Holders of VIGL
Also See: SEC filings
Below we present the annualized performance delivered by Vigil Neuroscience stock since 11-20-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Vigil Neuroscience insider buying occurred is the ultimate
test of whether insiders were right about VIGL being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/21/2023 |
|
End date: |
05/09/2024 |
|
Start price/share: |
$3.27 |
|
End price/share: |
$3.29 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
0.46% |
|
Annualized Gain: |
0.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,046.00 |
|
Years: |
0.46 |
|
Vigil Neuroscience Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Vigil Neuroscience insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding VIGL
|
|